1.Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH et al. Non-Hodgkin’s Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 2016; 14(9):1067-79. https:// doi: 10.6004/jnccn.2011.0046
2. Nguyen L, Papenhausen P, Shao H. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects. Genes. 2017; 8(4):1-23. https:// doi: 10.3390/genes8040116.
3. Wu FT, Lu L, Xu W, Li JY. Circulating tumor DNA: clinical roles in diffuse large B-cell lymphoma. Ann Hematol. 2019; 98(2):255-269. https:// doi: 10.1007/s00277-018-3529-9
4. Singh K, Gollapudi S, Mittal S, Small C, Kumar J, Ohgami RS. Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2. Diagnostics. 2021; 11(4):600. https:// doi: 10.3390/diagnostics11040600.
5. Chapuy B, Stewart Ch, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-90. https: // doi: 10.1038/s41591-018-0016-8.
6. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. https:// doi: 10.1056/NEJMoa1801445.
7. Müller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell. 2002; 111(2):197-208. https:// doi: 10.1016/s0092-8674(02)00976-5.
8. Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell. 2002; 111(2):185-96. https:// doi: 10.1016/s0092-8674(02)00975-3.
9. Martin-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, Wickham-Garcia E, et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood. 2009; 113(11):2488-97. https:// doi: 10.1182/blood-2008-04-152900
10. Bödör C, O’Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia. 2011; 25(4):726-9. https:// doi: 10.1038/leu.2010.311.
11.Oñate-Ocaña LF, Ponce-Martínez M, Taja-Chayeb L, Gutiérrez-Hernández O, Avilés-Salas A, Cantú-de-León D, et al. A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma. Rev Invest Clin. 2021. May 27. https:// doi: 10.24875/RIC.21000070.
12. Yap DB, Chu J, Berg T, Schapira M, Schapira M, Cheng SW, Moradian A, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011; 117(8):2451-9. https:// doi: 10.1182/blood-2010-11-321208
13. Wigle T, Knutson SK, Jin L, Kuntz KW, Pollock RM, Richon VM. The Y641 mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS lett. 2011; 585(19):3011-4. https:// doi: 10.1016/j.febslet.2011.08.018.
14. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA. 2010; 107(49):20980-5. https:// doi: 10.1073/pnas.1012525107.
15. Melani Ch, Wilson W, Roschewski M. Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA. Best Pract Res Clin Haematol. 2018; 31(3):285-292. https: // doi: 10.1016/j.beha.2018.07.004
16. Arzuaga-Mendez J, Prieto-Fernandez E, Lopez-Lopez E, Martin-Guerrero I, García-Ruiz JC, García Orad A. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review. Crit Rev Oncol Hematol. 2019; 139:7-15. https:// doi: 10.1016/j.critrevonc.2019.04.013.
17. Kallam A, Adusumalli J, Fu K, Armitage JO. Circulating tumor DNA in lymphomas: Era of precision medicine. Adv in cell and gene therapy. 2020; https://doi.org/10.1002/acg2.81
18. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. https:// doi: 10.1200/JCO.2013.54.8800.
19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649–55.
20. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103(1):275-82. https:// doi: 10.1182/blood-2003-05-1545.
21. Solis-Armenta R, Cacho-Díaz B, Gutiérrez-Hernández O, Candelaria-Hernández M. Central Nervous System International Prognostic Index Impacts Overall Survival in Diffuse Large B-Cell Lymphoma Treated with R-Chop in a third Level Cancer Center from Mexico: A Survey of 642 patients. Rev Invest Clin. 2021; 73(4):231-237. https:// doi: 10.24875/RIC.21000010.
22. Alcaide M, Yu S, Bushell K, Fornika D, Nielsen JS, Nelson BH, et al. Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. Clinical Chem. 2016; 62(9):1238-47. https:// doi: 10.1373/clinchem.2016.255315.
23. Rossi D, Spina V, Bruscaggin A, Gaidano G. Liquid biopsy in lymphoma. Haematologica. 2019; 104(4):648-652. https:// doi: 10.3324/haematol.2018.206177.
24. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015; 16(5):541-9. https:// doi: 10.1016/S1470-2045(15)70106-3.
25. Condoluci A, Rossi D. The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomas. Curr Opin Hematol. 2019; 26(4):281-287. https:// doi: 10.1097/MOH.0000000000000516.
26. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, et al. Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol. 2009; 20(8):1408-13. https:// doi: 10.1093/annonc/mdp006.
27. Camus V, Stamatoullas A, Mareschal S, Viailly PJ, Sarafan-Vasseur N, Bohers E, et al. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma Haematologica. 2016; 101(9):1094-101. https:// doi: 10.3324/haematol.2016.145102.
28. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. https:// doi: 10.1038/nrc3066.
29. Bohers E, Viailly PJ, Becker S, Marchand V, Ruminy P, Maingonnat C, et al. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer J. 2018; 8(8):74. https:// doi: 10.1038/s41408-018-0111-6.
30. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-cell Lymphoma. J Clin Oncol. 2018; 36(28):2845-2853. https:// doi: 10.1200/JCO.2018.78.5246.
31. Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AFM. Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016; 8 (364):364ra155. https:// doi: 10.1126/scitranslmed.aai8545.
32. Rossi D, Diop F, Spaccarotella E, Monti S, Zanni M, Rasi S, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017; 129 (14):1947-1957. https:// doi: 10.1182/blood-2016-05-719641.
33. Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016; 128(2):185-94. https:// doi: 10.1182/blood-2016-02-699520.
34.Coccaro N, Anelli L, Zagaria A, Perrone T, Specchia G, Albano F. Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? Cancers. 2020; 12(1):185. https:// doi: 10.3390/cancers12010185.
35. Kurtz DM. Prognostication with circulating tumor DNA: is it ready for prime time? Hematology Am Soc Hematol Educ Program. 2019; (1):47-52.
36. Rossi D, Kurtz DM, Roschewski M, Cavalli F, Zucca E, Wilson WH. The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA. Hematol Oncol. 2020; 38(1):34-37. https:// doi: 10.1002/hon.2704.
37. Camus V, Sarafan-Vasseur N, Bohers E, Dubois S, Mareschal S, Bertrand P, et al. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016; 57(9):2171-9. https:// doi: 10.3109/10428194.2016.1139703.
38. Dubois S, Mareschal S, Picquenot JM, Viailly PJ, Bohers E, Cornic M, et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy? Oncotarget. 2015; 6(18):16712-24. https:// doi: 10.18632/oncotarget.3154.
39. Morin RD, Johnson N, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin. Nat Genet 2010; 42(2): 181-185. https:// doi: 10.1038/ng.518.
40. Caganova M, Carrisi Ch, Varano G, Mainoldi F, Zanardi F, Germain PL, et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest. 2013; 123(12):5009-22. https:// doi: 10.1172/JCI70626.
41. Zhang J, Dominguez-Sola D, Hussein S, Lee J, Holmes AB, Bansal M, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015; 21(10):1190-8. https:// doi: 10.1038/nm.3940.
42. Nagy Á, Bátai B, Balogh A, Illés S, Mikala G, Nagy N, et al. Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma. Genes (Basel). 2020; 11(7):785. https:// doi: 10.3390/genes11070785.
43. Tuaeva NO, Falzone L, Porozov YB, Nosyrev AE, Trukhan VM, Kovatsi L, et al. Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievement. Cells. 2019; 8(10):1251. https:// doi: 10.3390/cells8101251.